Breakfast Sessions - Concurrent

Eli Lilly Breakfast Symposium
7:00am - 8:15am
Can technology assist us in the management of pregnancy complicated by diabetes?  
Riverbank 5

Roche Diagnostics Breakfast Symposium
7:00am - 8:15am
Discovering the Power of the Accu-Chek Bolus Advisor featuring the New Accu-Chek Connect System  
Room L1

Breakfast Meetings:

ADEA Award Judges Meeting
7:00am - 8:30am
Room L2

ESA-SRB/ADS-ADEA Presidents Breakfast
7:00am - 8:30am
Riverbank Boardroom

Concurrent Sessions

Joint ADS & ADEA Welcome
8:30am - 9:00am
Halls L & M
Presented by Nat Cook MP Member for Fisher on behalf of the Health Minister Jack Snelling MP

Chinese Session
8:30am - 10:30am
Riverbank 6, 7 & 8
Chair: Sof Andrikopoulos

8:30 AM  Haipeng Xiao
Opening

8:40 AM  Miao Yu
Epidemiology, achievements and strategy fighting against diabetes in China

9:00 AM  Ligang Zhou
The choice of OAD regimen in new onset type 2 diabetes patients

9:20 AM  Fan Zhang
The efficacy and safety of DPP-4 inhibitors in Chinese type 2 diabetes

9:40 AM  Yingying Luo
Basal Insulin Treatment in type 2 Diabetic Patients in China: ORBIT Study

10:00 AM  Yanbing Li
Insulin therapy in newly diagnosed type 2 diabetes: regimen of short-term intensive therapy and its effect on long-term glycemic control"

10:20 AM  Sof Andrikopoulos
Closing
**ADS Clinical Symposium: Hypoglycaemia**

8:30am - 10:30am  
Riverbank 2 & 3

*Recorded Session*

Chairs: Sophia Zoungas & Tim Jones  
This conference acknowledges the sponsorship of Abbott Diabetes Care

8:30 AM  
**Stephen Twigg**  
The enigma of the 'Dead in Bed' syndrome  
abs# 2

9:00 AM  
**Jane Holmes-Walker**  
Comparison of islet cell transplantation with medical therapy for management of severe hypoglycaemia in T1DM  
abs# 3

9:30 AM  
**Christel Hendriekx**  
Emotional and behavioural consequences of hypoglycaemia  
abs# 4

10:00 AM  
**Simon Heller**  
An evidence based approach to the clinical management of problematic hypoglycaemia  
abs# 5

**ADS Clinical Orals: Obesity**

8:30am - 10:30am  
Riverbank 4

Chairs: Spiros Fourlanos & Sarah Price

8:30 AM  
**Nada Cvijanovic**  
Intestinal fatty acid sensor (FFAR4) and transporter (CD36) expression are significantly correlated with body mass index, and are not altered by acute fat exposure in lean, overweight or obese humans  
abs# 6

8:45 AM  
**Amy T Hutchison**  
Predictors of susceptibility to weight change during a single cycle of weight gain and loss  
abs# 7

9:00 AM  
**Richard L Young**  
Increased Capacity for Intestinal Serotonin Release in Obese and Diabetic Humans  
abs# 8

9:15 AM  
**John Prins**  
Liraglutide 3.0 mg for weight management in obese/overweight adults with type 2 diabetes: Results from the SCALE Diabetes 56-week randomised, double-blind, placebo-controlled trial  
abs# 9

9:45 AM  
**Joseph Proietto**  
Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in overweight and obese adults: the SCALE Obesity and Prediabetes randomised trial  
abs# 10

10:00 AM  
**Sue Lynn Lau**  
Differences in postpartum weight retention in Caucasian, Oriental and Indian-Subcontinental women, 3 months following a GDM pregnancy. Causes, and implications for future risk.  
abs# 11

10:15 AM  
**Shan Jiang**  
Pregnancy Outcomes in Women with Gestational Diabetes under the Old ADIPS and New IADPSG Diagnostic Criterias  
abs# 12

**ADS Basic Orals: Metabolic Regulation and Exercise**

8:30am - 10:30am  
Room L1

Chair: Leonie Heilbronn & Jon Whitehead

8:30 AM  
**2014 ADS Skip Martin Early Career Fellowship Awardee**  
**Michael A Pearen**  
The orphan nuclear receptor 4A subgroup, exercise and metabolic regulation  
abs# 14

8:45 AM  
**Chrysovalantou E Xirouchaki**  
Impaired exercise capacity in muscle-specific Gys1- KO mice.  
abs# 15

9:00 AM  
**Chelsea Arceri**  
Childhood is a critical period for life: long-term effects of early-life exercise on glucose tolerance and mitochondrial capacity  
abs# 16

9:15 AM  
**Greg M Kowalski**  
Reversal of high-fat diet-induced metabolic dysfunction: tracing the reverse route  
abs# 17

9:30 AM  
**Darren C Henstridge**  
Substrains of C57BL/6J mice display altered metabolic traits suggestive of metabolic drift.  
abs# 18

Australian Diabetes Society and the Australian Diabetes Educators Association  
Annual Scientific Meeting 2015
Jacqueline Stoeckli
Kinome Screen Identifies PFKFB3 and Glucose Metabolism as Important Regulators of the Insulin/IGF-1 Signalling Pathway  abs# 19

Amanda E Brandon
Deletion of Grb10 specifically in skeletal muscle leads to an increase in muscle mass and insulin sensitivity in 1 year old mice  abs# 20

Xiang Zhang
Comparative effects of bile diversion and duodenal jejunal bypass on glucose and lipid metabolism in diabetic rats  abs# 21

Plenary Presentations

ADS & ESA Joint Plenary
9:00am - 9:45am  Halls L & M
*Recorded Session*
Chair: Timothy Davis

9:00 AM
Steven Kahn
The Beta Cell in Type 2 Diabetes: From The Clinic to The Lab  abs# 1

ADEA Plenary
9:45am - 10:30am  Halls L & M
*Recorded Session*
Chair: Tracy Aylen

9:45 AM
Vibeke Zoffman
Realizing empowerment in practice through Guided Self-Determination  abs# 22

ADS & ADEA Morning Tea
10:30am - 11:00am  Exhibition Hall
This conference acknowledges the sponsorship of Roche

Concurrent Sessions

ADEA Guidelines for Managing Diabetes and Cancer
10:30am - 11:30am  Riverbank 5
Chair: Elizabeth Mulrooney

10:30 AM
Laita Bokhan
Guidelines for managing Diabetes and Cancer  abs# 23
Presented by:
Elizabeth Mulrooney
Richard Maclsaac
Laita Bokhari
Peter Colman
Mark Rosenthal

ADEA Oral Presentations: Applying Evidence Based Decisions to Practice
11:00am - 1:00pm  Halls L & M
*Recorded Session*
Chairs: Ann Bush & Annabel Thurlow

11:00 AM
Jane Giles
Diabetes inpatient model of care; A rural experience  abs# 24

11:12 AM
Simone L Patterson
Case Study: Use of Continuous Glucose Monitoring In A Hospital Inpatient With Type 1 Diabetes To Alert Hypoglycaemic Episodes  abs# 25
11:24 AM  Brett Fenton  
Hypoglycaemia Management of Adult Inpatients with Diabetes  abs# 26

11:36 AM  Trisha Dunning  
Hypoglycaemia in residential aged care  abs# 27

11:48 AM  Sally Double  
Ironman; the implications for type 1 diabetes management  abs# 28

12:00 PM  Pauline Hill  
Diabetes Educator perspectives about annual Flu vaccinations  abs# 29

**ADS & ESA Joint Symposium: Oxidative Stress**

11:00am - 1:00pm  Riverbank 6, 7 & 8
Chairs: Josephine Forbes and Stephen Twigg

11:00 AM  Steven Kahn  
ß-cell Apoptosis: The Role of Apoptosis Repressor with CARD Domain (ARC)  abs# 30

11:30 AM  Karin Jandeleit-Dahm  
Reactive oxygen species and diabetic complications  abs# 31

12:00 PM  Kerry-Anne Rye  
Impact of HDL on Oxidative Stress in Diabetes  abs# 32

12:30 PM  Mark E Cooper  
Advanced Glycated Products  abs# 33

**NADC Symposium**

11:00am - 1:00pm  Riverbank 2 & 3
*Recorded Session*
Chair: Sophia Zoungas

11:00 AM  Natalie Wischer  
NADC – Reaping the rewards of Membership. Presentation of NADC projects and resources.  abs# 34

11:20 AM  Tim Jones  
New Diabetes Technologies: Pathways to Reimbursement  abs# 35

11:40 AM  Spiros Fourlanos  
BioGrid Diabetes Database in Australia: tips and tricks  abs# 36

12:00 PM  Gowri Somarajah  
Quality improvements using ANDA: Australian National Diabetes Audit- Australian Quality Self-Management Audit 2014  abs# 37

12:20 PM  Heather Hart  
How has ANDA data led to Quality Improvements  abs# 38

Session followed by NADC Q&A

**ADS Basic Symposium: Neural Control and Programming**

11:00am - 1:00pm  Room L1
Chairs: Jenny Gunton & Greg Cooney

11:00 AM  Jens Brüning  
Neonatal insulin action impairs hypothalamic neurocircuit formation in response to maternal high fat feeding  abs# 39

11:30 AM  Tony Tiganis  
CNS control of WAT browning  abs# 40

12:00 PM  Jenny E Gunton  
Browning of white fat for treating obesity  abs# 41

12:30 PM  Catherine Suter  
Epigenetic inheritance and the legacy of parental obesity  abs# 42

**ADS Clinical Orals: Type 1 Diabetes**

11:00am - 1:00pm  Room L3
Chairs: Jane Holmes-Walker & Jennifer Conn

The conference acknowledges the sponsorship of Eli Lilly
11:00 AM  John M Wentworth  
A combination of 15 SNPs and clinical features in relatives with islet autoantibodies improves prediction of Type 1 Diabetes: implications for prevention trials.  abs# 43

11:15 AM  Dilshani Jayawardene  
A Feasibility Study of a Novel Redundant Electrochemical Sensor for Continuous Glucose Monitoring in Patients With Type 1 Diabetes (T1d)  abs# 44

11:30 AM  Sybil A McAuley  
The Performance of an Orthogonally Redundant Glucose Sensor compared to a Simply Redundant Electrochemical Glucose Sensor in Adults with Type 1 Diabetes  abs# 45

11:45 AM  Julio Rosenstock  
LY2963016 Insulin Glargine (LY IGlar) Compared with Lantus® Insulin Glargine (IGlar) in Patients with Type 1 Diabetes Mellitus (T1DM): Efficacy, Safety, and Patient-reported Outcomes from the ELEMENT-1 Study  abs# 46

12:00 PM  Angela S Lee  
Metabolic syndrome in type 1 diabetes: exploring the prevalence of ‘double diabetes’ and the risk of diabetes complications in the Australian National Diabetes Information Audit and Benchmarking (ANDIAB) Initiative  abs# 47

12:15 PM  Jencia Wong  
Mortality in Type 1 Diabetes is Increased in the Presence of the Metabolic Syndrome, but Remains Lower than in Young Onset Type 2 Diabetes  abs# 48

12:30 PM  Melissa H Lee  
Diabetic Ketoacidosis in Adult Patients – An audit of factors influencing time to normalisation of metabolic parameters.  abs# 49

12:45 PM  Azni Abdul-Wahab  
Creatinine is Falsely Elevated in Diabetic Ketoacidosis Patients: A Comparison of 4 Jaffe Assays with an Enzymatic Method.  abs# 50

ADEA Masterclass: Private Practice Business Essentials
11:00am - 1:00pm  City Room 3 & 4
*Recorded Session*
Chairs: Jayne Lehmann & Catherine Anderson

11:00 AM  Nicole Swain  
Private practice business essentials  abs# 51
Including a panel of private practitioners

ADEA Oral Presentations: Paediatric Care in Diabetes
11:30am - 1:00pm  Riverbank 5
Chairs: Heather Hart & Jenny Thomas

11:30 AM  Karen Crawford  
Ongoing Evaluation of the Documentation for Managing Type 1 Diabetes at School and Preschool  abs# 52

11:42 AM  Virginia Hagger  
Perspectives of a 2-Day Support Program for Parents of Adolescents with Type 1 Diabetes – The TEAM T1 Program  abs# 53

11:54 AM  Kimberley Duggan-Larkin  
Reach and Response to a 5-Day Structured-Education Program for Adolescents with Type 1 Diabetes – The TEAM T1 Program  abs# 54

12:06 PM  Bodil Rasmussen  
Developing an Online Guided Self-Determination Program for Young Adults with Diabetes: Methodological Considerations  abs# 55

12:18 PM  Karen Crawford  
Mastering Diabetes – Developing a Suite of Resources for Schools, Preschools and Families About Managing Type 1 Diabetes  abs# 56

12:30 PM  Lindsey Webb  
How would type 1 diabetes ambulatory care be different if it was consumer driven?  abs# 57
ADS & ADEA Lunch
1:00pm - 2:00pm   Exhibition Hall

Yoga Class
1:00pm - 1:45pm   City Room Foyer
This is a ticketed event

Lunchtime Meetings:

ADEA Private Practice Meeting
1:00pm - 2:00pm   City Room 3 & 4
Chair: Jayne Lehmann

ADEA Past Presidents Meeting
1:00pm - 2:00pm   Riverbank Boardroom

ADEA Clinical Practice Committee
1:00pm - 2:00pm   City Suite 2

ADEA Branch Chairs Meeting
2:00pm - 3:00pm   Riverbank Boardroom

NADC Expert Forum
1:15pm - 2:00pm   Riverbank 2 & 3
*Recorded Session*
Chair: Sophia Zoungas

  Cathy Balding
  Improving quality – where it counts abs# 58

ADS Basic Poster Discussions
2:00pm - 3:00pm   Exhibition Hall
Please see poster listing for all presenters

ADEA Poster Viewing One
2:00pm - 3:00pm   Exhibition Hall
Please see poster listing for all presenters

Plenary

ADS Plenary Lectures
2:00pm - 3:00pm   Halls L & M
*Recorded Session*
Chair: Mark Cooper
2:00 PM

Julio Rosenstock
Update on Combination Basal Insulin Plus GLP-1 Receptor Agonist: how far have we gone? abs# 63
This conference acknowledges the sponsorship of AstraZeneca

2:30 PM

Simon Heller
Does hypoglycaemia oppose the macrovascular benefits of intensive glucose control? abs# 64
This conference acknowledges the sponsorship of Eli Lilly
Concurrent Sessions

ADEA Symposium: Diabetes Management in Disasters
1:30pm - 3:30pm
Panorama 1, 2 & 3
Chair: Alicia Jenkins

1:30 PM  Alicia Jenkins
Overview of Diabetes and Disasters and Outline of the Disaster Management Project in Progress  abs# 59

1:45 PM  Penny Burns
What does the evidence show about the consequences of disasters on diabetes and other chronic conditions? What does this mean for preparedness?  abs# 60

2:00 PM  Amy Marcos
The role of a Credentialled Diabetes Educator is not well documented in managing individuals with diabetes before, during and after a natural disaster.  abs# 61

2:15 PM  Benjamin Ryan
Exploring impact of cyclone, flood and storm related disasters on public health infrastructure and the management of non-communicable diseases.  abs# 62

ADEA: Vibeke Zoffmann Masterclass
2:00pm - 3:00pm
Riverbank 2 & 3
*Recorded Session*
Chair: Liz Obersteller

2:00 PM  Vibeke Zoffmann
Hands on Guided Self-Determination (GSD)  abs# 65

Bioscientifica Symposium
2:00pm - 3:30pm
Riverbank 5
Chair: Sof Andrikopoulos

2:00 PM  Sof Andrikopoulos
Introduction

2:05 PM  Wayne Tilley
The manuscript submission process

2:15 PM  Chris O’Neill
The peer review process

2:25 PM  Mark Cooper
Responding to reviewer comments

2:35 PM  Ken Ho
Publishing ethics

2:45 PM  Warrick Inder
Open access

2:55 PM  Ross Laybutt
Increasing the impact of your work

3:05 PM  Question and answer session

ADS & ADEA Afternoon Tea
3:00pm - 3:30pm
Exhibition Hall

This conference acknowledges the sponsorship of Servier
Concurrent Sessions

ADEA Resource for Diabetes in Aged Care Forum
3:30pm - 4:00pm
*Recorded Session*
Chair: Rachel McKeown

Caroline Thomas
Resources for Diabetes in Aged Care  abs# 66
Presented by:
Caroline Thomas and Rachel McKeown

ADS Debate: Type 2 Diabetes - After Metformin, Then What?
3:30pm - 5:30pm
*Recorded Session*
Chair: Sophia Zoungas

This conference acknowledges the sponsorship of AstraZeneca
Presented by:
Richard O'Brien
Jonathon Shaw
Tim Davis
Jenny Gunton
Trisha O'Moore-Sullivan
Stephen Colaguiri

ADEA Symposium: Better Understanding the Needs of Your People with Diabetes: A Behavioural Perspective
3:30pm - 5:30pm
*Recorded Session*
Chairs: Jane Speight & Ann Morris

Jane Speight
Better Understanding the Needs of Your People with Diabetes: A Behavioural Perspective  abs# 67
Presented by:
3:30 PM  Virginia Hagger
Understanding diabetes distress and its implications among adolescents with type 1 diabetes
4:00 PM  Vibeke Zoffmann
How to meet the complex needs of young adult women with type 1 diabetes and high HbA1c
4:30 PM  Amelia Lake
Engaging young adults with type 2 diabetes in retinal screening: do they need information, motivation or skills?
5:00 PM  Jessica Browne
Young adults with type 1 and 2 diabetes: more similar than you may think

ADS Clinical Orals: Gut and Glycaemia
3:30pm - 5:30pm
Chairs: Michael Horowitz & Jerry Greenfield

3:30 PM  Peter Clifton
Effect of fructose in a solid meal on glucose, insulin and triglyceride responses compared with sucrose and sucralse in healthy people.  abs# 68
3:45 PM  Linda E Mignone
A low-dose whey protein preload slows gastric emptying and improves post-prandial glycaemia in type 2 diabetes  abs# 69
4:00 PM  Tongzi Wu
Comparative effect of intraduodenal and intrajejunal glucose infusion on the gut-incretin axis response in healthy males  abs# 70
4:15 PM  Chinmay S Marathe
The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility,
flow, transit and absorption of glucose in health and type 2 diabetes: a randomised controlled trial. abs# 71

4:30 PM
Kirsty Turner
Effect of red meat and dairy on insulin sensitivity abs# 72

4:45 PM
Kirsten E Peters
Plasma β-amyloid in cognitively normal people with or without type 2 diabetes: A matched case-control study abs# 73

5:00 PM
Natalie Kwai
Glucose variability: a factor in the development of diabetic neuropathy? abs# 74

5:15 PM
Paul Williams
Quality of HbA1c measurements in Australia – A Report from the RCPAQAP abs# 75

ADS Basic Symposium: Insulin Resistance
3:30pm - 5:30pm
Room L1
Chairs: Jacqueline Stoeckli & Carsten Schmitz-Peiffer

3:30 PM
Christopher G Proud
Roles of the MNKs (MAP kinase-interacting kinases) in metabolic disease abs# 76

4:00 PM
Matthew Watt
Perilipin 5 regulates lipid metabolism and insulin action abs# 77

4:30 PM
Paul Gregorevic
Exploring the TGF-beta network as a regulator of muscle growth and metabolism abs# 78

5:00 PM
Rebecca Robker
Impact of metabolic syndrome on female fertility and offspring mitochondrial inheritance abs# 79

ADEA Wellness & Resilience Masterclass
3:00pm - 5:30pm
Panorama 1, 2 & 3
Chairs: Brett Fenton & Lily Mountain

3:00 PM
Gabrielle Kelly
Well-being and Resilience Masterclass abs# 80

Presented by:
Gabrielle Kelly
Ann Calvert

ADS Basic Orals: Diabetes Complications
3:30pm - 5:30pm
Riverbank 5
Chair: Susan McLennan & Linda Gallo

3:30 PM
2014 ADS Skip Martin Early Career Fellowship Awardee
Stephen P Gray
The Role of Nox5 in Diabetes Associated Vascular Disease abs# 81

3:45 PM
Abhirup Das
Nicotinamide mononucleotide, a NAD+ precursor, protects against diabetes-induced vascular defects in a Sirt1-dependent manner abs# 82

4:00 PM
Brian G Drew
ERα-regulated Lipocalin 2 Expression in Adipose Tissue Links Obesity with Breast Cancer Progression abs# 83

4:15 PM
Anna C Calkin
A Combined Genetics and Proteomics Approach to Identify Novel Regulators of Triglyceride Metabolism abs# 84

4:30 PM
Mark Gorrell
Metabolic and anti-fibrogenic outcomes of targeting the protease Fibroblast Activation Protein (FAP) abs# 85

4:45 PM
Danqing Min
Monocyte Surface and Soluble Levels of the Haemoglobin Scavenger Receptor CD163: Possible Role in the Development of Diabetes Complications abs# 86
5:00 PM  Karly Sourris  
Elucidating the interactions between glucagon-like peptide-1 (GLP-1) and the receptor for ages (rage) pathways in diabetic nephropathy  abs# 87

5:15 PM  Susan McLennan  
Macrophage Polarisation Markers in the Development of Diabetic Kidney Disease  abs# 88

**ADS & ADEA Welcome Function**  
5:30pm - 7:00pm  Exhibition Hall

*This conference acknowledges the sponsorship of Novartis Pharmaceuticals*
SCIENTIFIC PROGRAM
Thursday 27th August, 2015

Breakfast Sessions - Concurrent

Novo Nordisk Breakfast Symposium
7:00am - 8:15am
Rethink Obesity
Riverbank 6, 7 & 8

Sanofi Breakfast Symposium
7:00am - 8:15am
Why every hypo matters....
Riverbank 2 & 3

Abbott Diabetes Care Breakfast Symposium
7:00am - 8:15am
A New Era in Glucose Monitoring: Flash Glucose Monitoring and Ambulatory Glucose Profile (AGP)
Riverbank 5

Plenary

ADEA Plenary
9:00am - 10:00am
Halls L & M
*Recorded Session*
Chair: Giuliana Murfet
9:00 AM
Timothy Olds
Stress, lifestyle and diabetes: using the allostatic load model to translate research into practice
abs# 109

Concurrent Sessions

ADS Clinical Young Investigator Awards
8:30am - 10:30am
*Recorded Session*
Riverbank 6, 7 & 8
Chairs: Jenny Gunton & N Wah Cheung
8:30 AM
Amin Sharifi
Impact of Overnight Home Closed Loop (CL) Insulin Delivery on Glycaemic Control and Counter-Regulatory Hormones Compared to Sensor Augmented Pump Therapy with Low Glucose Suspend (SAP-LGS) in Patients with Type 1 Diabetes (T1D)  abs# 89

8:45 AM
Palash Kar
Personalised Glucose Therapy: Glucose Targets in Critically Ill Patients with Pre-Existing Poorly Controlled Type 2 Diabetes  abs# 90

9:00 AM
Mark P Plummer
Hyperglycaemia potentiates GLP-1 induced slowing of gastric emptying  abs# 91

9:15 AM
Laurence G Trahair
Effects of exogenous glucagon-like peptide-1 on the blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in healthy older subjects and type 2 diabetes.  abs# 92

9:30 AM
Maria I Constantino
The use of systematic data collection on retinopathy to assess prior glycaemic control: The Hubble telescope equivalent of looking back in time  abs# 93
9:45 AM  Ria Arnold
Examining the effects of diabetic kidney disease on neuropathy severity and nerve excitability: a comparative study  abs# 94

10:00 AM  Katherine Tonks
Bone is another casualty in the war against insulin resistance, as it remains insulin-sensitive.  abs# 95

10:15 AM  I-Lynn Lee
The perinatal outcomes of women in the Northern Territory with diabetes in pregnancy: The PANDORA Study  abs# 96

**ADS Basic Symposium: Obesity, Metabolic Stress and Liver Disease**
8:30am - 10:30am  Riverbank 2 & 3
Chairs: Mark Febbraio & Matthew Watt

**This conference acknowledges the sponsorship of Roche Diagnostics Australia**

8:30 AM  Michael Karin
Metabolic stress, autophagy and liver cancer  abs# 97

9:00 AM  Geoffrey Farrell
Cholesterol Lipotoxicity Causes Nash: Current Evidence, Mechanistic Pathways, and Therapeutic Implications  abs# 98

9:30 AM  Jacob George
Management of Non-Alcoholic Steatohepatitis  abs# 99

10:00 AM  Mark Febbraio
Therapeutic strategies to prevent liver inflammation and fibrosis  abs# 100

**ADS Basic Orals: Beta Cells**
8:30am - 10:30am  Riverbank 5
*Recorded Session*
Chairs: Charmaine Simeonovic & Kathryn Aston-Mourney

8:30 AM  Ann M Simpson
Gene Therapy For Diabetes: Reversal Of Diabetes In A Humanised Mouse Model  abs# 101

8:45 AM  Mugdha Joglekar
Human Islet-derived Progenitor Cells regulate T-cell proliferation via exosomal transfer of microRNAs  abs# 102

9:00 AM  Jeng Yie Chan
JNK regulates the transition from XBP1-mediated adaptive unfolded protein response to β-cell death in type 1 and type 2 diabetes  abs# 103

9:15 AM  Kwan Yi (Connie) Chu
High-fat diet-induced autophagy protects against endoplasmic reticulum stress and death but suppresses insulin secretion in pancreatic beta-cells  abs# 104

9:30 AM  Kim Loh
Regulation of insulin secretion from pancreatic islets via the Y1 receptor signalling  abs# 105

9:45 AM  Sarita Dhounchak
Rescue of beta cells by heparan sulfate (HS) replacement in Type 2 diabetes (T2D)  abs# 106

10:00 AM  Smithamol Sithara
A Gene Expression Signature for β-cell failure  abs# 107

10:15 AM  Anandwardhan A Hardikar
Understanding a bugs life in the fat land  abs# 108

**ADS & ADEA Morning Tea**
10:30am - 11:00am  Exhibition Hall

**This conference acknowledges the sponsorship of Diabetes Australia**
Concurrent Sessions

**ADS Kellion Award Lecture**
11:00am - 12:00pm
*Recorded Session*
Chair: Sof Andrikopoulos
11:00 AM  
Stephen Colagiuri

**ADS Annual General Meeting**
12:00pm - 1:00pm
Halls L & M
Only ADS members are able to attend the Annual General Meeting

**ADEA Symposium: Diabetes Education in a World of Social Media**
11:00am - 1:00pm
Riverbank 6, 7 & 8
*Recorded Session*
Chairs: Jayne Lehmann & Caroline Ford
11:00 AM
David Rawlings
Diabetes education in a world of social media  
abs# 111
Presented by:
Eliza Bartlett  
Gary Wittert  
Helen Edwards

**ADEA Oral Presentations: Diabetes Management in Cultural and Ethnic Groups**
11:00am - 1:00pm
Riverbank 2 & 3
Chairs: Ann Morris & Barbie Sawyer
11:00 AM
Sean M Taylor  
Depression and diabetes in the Torres Strait  
abs# 112
Jennifer A Halliday
The National Diabetes Service Scheme (NDSS) Diabetes and Mental Health Handbook: A ‘7As’ model for identifying and addressing psychological problems in diabetes consultations  
abs# 113
11:12 AM
Rickie Myszka
Identifying Diabetes Risk factors in Indigenous Australian living in Western Sydney  
abs# 115
11:24 AM
Adriana D Ventura
Social Support and Social Control in Type 2 Diabetes: an Interview Study  
abs# 116
11:36 AM
Tammie Choi
Culturally Tailored Diabetes Education for Chinese Patients: a Qualitative Case Study  
abs# 114
11:48 AM
Trisha Dunning
Designing clinical guidelines for older people with diabetes: methodological and clinical challenges  
abs# 118
12:00 PM
Vivienne Chuter
Lower limb vascular assessment for people with diabetes: a multifaceted assessment of objective screening techniques  
abs# 121

**ADEA Oral Presentations: Clinical Challenges in Diabetes Management**
11:00am - 1:00pm
Riverbank 4
Chairs: Fran Brown & Gillian Krenzin
11:00 AM
Gael Holters
Continuous Glucose Monitoring – stand alone: Does it effect change in the real world?  
abs# 119
11:12 AM
Katrina Reynolds
Foot Health Intervention in Children and Young People with Diabetes: A Pilot Study  
abs# 120
11:24 AM
Vivienne Chuter
Lower limb vascular assessment for people with diabetes: a multifaceted assessment of objective screening techniques  
abs# 121
11:48 AM

Rebecca Munt
Factors influencing self management for working class males with Type 2 Diabetes Mellitus (T2DM)
abs# 122

A DEA: Writing for a Publication
11:00am - 1:00pm
*Recorded Session*
* Pre registration for this session is essential
Chair: Helen Vaughan
11:00 AM
Vy Le
Writing for publication  abs# 123
Presented by:
Helen Vaughan
Lea Sorensen
Anne Marks
Vy Le and
Kate Marsh
Panel discussion to follow

ADS & ADEA Lunch
1:00pm - 2:00pm
Exhibition Hall

Yoga Class
1:00pm - 1:45pm
City Room Foyer
This is a ticketed event

Lunchtime Meetings:

A DEA Credentialling Committee
12:00pm - 1:30pm
Riverbank Boardroom

ADS Meet the Expert
1:15pm - 2:00pm
Riverbank 2 & 3
Arya Sharma
5As of Obesity Management - a Practical Approach  abs# 124

ADS Meet the Expert
1:15pm - 2:00pm
Riverbank 4
Spiros Fourlanos
Are you sure it is type 2 diabetes?  abs# 125

Concurrent Sessions

A DEA Symposium: Diabetes at School and Preschool
1:30pm - 3:30pm
*Recorded Session*
Chair: Karen Crawford
Karen Crawford
Diabetes at School and Preschool Symposium  abs# 126
Presented by:
Sonia and Gillian Taylor
Fergus Cameron
Nuala Harkin
Helen Edwards,
Ellen Edmonds-Wilson
Ian Lumb
ADEA Research Workshop

1:30pm - 3:30pm

*Recorded Session*

*Pre registration for this session is essential*

Chair: Joanne Ramadge

Debra Kay
ADEA Research Workshop abs# 127

Presented by:
Joanne Ramadge
Guilliana Murfet
Jeric Uy
Members of the Reasearch Team from University of South Australia

1:30 PM
Introduction to the ADEA Framework, Research Register and Toolkit

1:45 PM
Group activity: Explore the Register

2:00 PM
Group activity: identify participants’ current research practice, interests and priorities

2:15 PM
Presentation: The Toolkit - introduction to EBP (ie the first part of the Toolkit) & Toolkit overview

2:35 PM
Group activity: Explore the Toolkit and how we might best use it to enhance practice

3:05 PM
Individual/pair activity: identify personal research priorities and plans

3:15 PM
Wrap up/Recommendations from the group to ADEA re future priorities to support and active research culture

3:30 PM
Close

Plenary

ADS Plenary Lecture

2:00pm - 3:00pm

*Recorded Session*

Chair: Mark Febbraio

2:00 PM
Michael Karin
The oil that feeds the flame: obesity, NASH and liver cancer abs# 128

2:30 PM
Jens Brüning
Neural control of obesity and type 2 diabetes abs# 129

This conference acknowledges the sponsorship of Novo Nordisk

Concurrent Sessions

ADS Clinical Poster Prize Presentations

2:00pm - 3:00pm

Please see poster listing for presenters

ADS Clinical Poster Viewing

2:00pm - 3:00pm

Please see poster listing for presenters

A DEA Poster Viewing Two

2:00pm - 3:00pm

Please see poster listing for presenters

A DEA Credentialling and Mentoring Forum

2:00pm - 3:00pm

Chair: Rachel McKeown

Rachel McKeown and Credentialling Committee

Credentialling and Mentoring abs# 152
Australian Diabetes Society and the Australian Diabetes Educators Association
Annual Scientific Meeting 2015

 ADS & ADEA Afternoon Tea
3:00pm - 3:30pm
Exhibition Hall

ADEA Oral and Poster Award Moderation
3:00pm - 4:00pm
Riverbank Boardroom

Concurrent Sessions

ADEA Symposium: Nutrition Through the Life Stages - From Conception to Adulthood
3:30pm - 5:30pm
Halls L & M
*Recorded Session*
Chair: Rachel McKeown & Michelle Tong
3:30 PM  Peter Clifton
   Diets for CVD protection   abs# 153
3:30 PM  Heather Gilbertson
   Translating dietary evidence to the kitchen table in kids and teens   abs# 154
3:30 PM  Kyra A Sim
   Building the foundation for life   abs# 155

ADS Pincus Taft Young Investigators Award Session
3:30pm - 5:30pm
Riverbank 6, 7 & 8
*Recorded Session*
Chair: Ross Laybutt & Josephine Forbes
3:30 PM  Weiyi Chen
   α-melanocyte stimulating hormone regulates glucose homeostasis via melanocortin-5 receptor expressed in skeletal muscle.   abs# 156
3:45 PM  Ryan Farr
   Predicting islet cell death using miRNAs: small molecules giving big insights.   abs# 157
4:00 PM  Christopher Meoli
   Long term high-fat-diet feeding reveals diet as a major regulator of age-related diseases.   abs# 158
4:15 PM  Jingjing He
   Identification and characterisation of the interferome: A novel regulator of adipogenesis implicated in the modulation of local and systemic insulin sensitivity   abs# 159
4:30 PM  Sarah Glastras
   Chronic kidney disease in offspring of obese mothers is exacerbated by diabetes   abs# 160
4:45 PM  Sherman Leung
   Human soluble receptor for advanced glycation end products therapy delays autoimmune diabetes in the non-obese diabetic mouse   abs# 161
5:00 PM  Vanessa R Haynes
   Neuronal fatty acid translocase regulates energy balance in high-fat fed mice   abs# 162
5:15 PM  Amit Lalwani
   Absence of HIF-1α and Coxsackie Virus Infection: Two Sides of the Same Coin in the Development of Type 1 Diabetes (T1D)   abs# 163

ADS Clinical Orals: Therapies for Type 2 Diabetes
3:30pm - 5:30pm
Riverbank 2 & 3
Chairs: Jeff Flack & Tang Wong
3:30 PM  Julio Rosenstock
   LY2963016 Insulin Glargine (LY IGlar) Compared with Lantus® Insulin Glargine (IGlar) in Patients with Type 2 Diabetes Mellitus (T2DM): Efficacy, Safety, and Patient-reported Outcomes from the ELEMENT-2 Study   abs# 164
3:45 PM  Stephen Twigg
   Age, BMI and Diabetes Duration: Effect on Glycaemic Control and Hypoglycaemia with Insulin Glargine 300 U/mL in Type 2 Diabetes   abs# 165
Julio Rosenstock
Advancing Basal Insulin Glargine with Prandial Lixisenatide QD vs Insulin Glulisine QD or TID in T2DM: The GetGoal-Duo2 Evidence-Based Trial (NCT01768559) abs# 166

Jonathan E Shaw
Characteristics Associated With Greater A1C Response to Exenatide Twice Daily at 6 Months abs# 167

Chinmay S Marathe
Effects of exenatide on the blood pressure and heart rate responses to intraduodenal glucose in type 2 diabetes abs# 168

Ted Wu
Effect of Empagliflozin Compared with Glimperide as Add-on to Metformin for 2 Years on the Amount and Distribution of Body Fat in Patients with Type 2 Diabetes (T2DM) abs# 169

Fahid Hashem
Diabetic Ketoacidosis (DKA) associated with SGLT2i use in T2DM – First case reports in Australia. abs# 170

David M Hoffman
10-year trends in glycaemic control, chronic kidney disease and use of diabetic medication in patients with type 2 diabetes (T2DM) - an Australian DINGO (Diabetes Informatics Group) multicentre study of over 11,000 patients seen in private endocrine practice abs# 171

**ADS Clinical Symposium: Epidemiology**

3:30pm - 5:30pm Riverbank 4

Chairs: Barbora de Courten & Wendy Davis

3:30 PM Catherine Itsiopoulos
Role of AGEs in aetio-pathogenesis of type 2 diabetes abs# 172

4:00 PM Negar Naderpoor
Role of vitamin D in cardiometabolic syndrome abs# 173

4:30 PM Barbora de Courten
Carnosine- a novel therapy for chronic diseases abs# 174

5:00 PM Helen Barrett
Inside Out, Who’s in charge? abs# 175

**ADEA Person Centred Care**

4:00pm - 5:30pm Riverbank 5

*Recorded Session*

Chair: Toni Rice

Toni Rice
Person Centred Care abs# 176

Presented by:

Toni Rice
Debra Kay
Louise Wiles
Lorraine Pitman

**Conference Dinner**

7:00pm - 11:30pm Hall F&G

This is a ticketed event
Please review Product Information before prescribing.
Full Product Information is available from Sanofi at

Minimum Product Information Toujeo (insulin glargine) Indications: Treatment of diabetes mellitus in adults. Contraindications: Hypersensitivity to insulin glargine or any of the excipients. Precautions: Not recommended for treatment of diabetic ketoacidosis; hypoglycaemia; switching between insulin glargine 100 U/mL and Toujeo; switching between other insulins and Toujeo; intercurrent illness; insulin antibodies; insulin label must always be checked before each injection to avoid medication errors between Toujeo and other insulins; pregnancy category B; lactation; careful glucose monitoring and dose adjustments may be necessary in elderly patients; not studied in children; renal and hepatic impairment. Interactions: Oral antidiabetic medicinal products; cardiovascular, ana glycaemic, anti-inflammatory, neurological, antipsychotic agents (see full PI); antibiotics; corticostroides; other hormonal therapies (see full PI); diuretics; protease inhibitors; sympathomimetic agents; lithium; alcohol; sympatholytics including B-blockers; others. See full PI. Adverse Effects: Hypoglycaemia; visual impairment; injection site reactions; others. See full PI. Dosage and Administration: Subcutaneous, once daily. Not for intravenous use. Dose adjustment may be required e.g. if patient’s weight or life-style changes or change in timing of insulin dose. The desired blood glucose levels as well as doses and timing of anti-diabetic medication must be determined and adjusted individually. Instruct patients to never re-use a needle. Toujeo must not be drawn from the cartridge of the pre-filled pen into a syringe. Insulin glargine 100 U/mL and Toujeo are not bioequivalent and are not directly interchangeable. Toujeo must not be diluted or mixed with any other insulin products. When switching from insulin glargine 100 U/mL or other basal insulin products to Toujeo, dose may need to be adjusted. Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter. ≥18 years. Date reviewed: 1 July 2016 Reference Document: P1, 30 June 2015.

PBS information: Lantus SoloSTAR and Lantus cartridges are listed on the PBS as a long acting insulin analogue for the treatment of type 1 and type 2 diabetes.


Minimum Product Information Lantus (insulin glargine) Indications: Once-daily subcutaneous administration for type 1 diabetes mellitus patients (adults and children) and type 2 diabetes mellitus patients (adults) who require insulin for control of hyperglycaemia. Contraindications: Hypersensitivity to insulin glargine or any excipient. Precautions: Hypoglycaemia; hepatic, renal and visual impairment; lipodystrophy and other injection site reactions; antibody production; intercurrent conditions; not studied in children <2 years; pregnancy category B; lactation; not intended for i.v. use; not recommended for treatment of diabetic ketoacidosis; LANTUS MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. Instruct patient to check insulin label before each injection to avoid accidental mix-ups between insulins. Interactions: Oral antidiabetic agents; cardiovascular, ana glycaemic, anti-inflammatory, neurological, antipsychotic agents (see full PI); antibiotics; corticosteroids; other hormonal therapies (see full PI); diuretics; protease inhibitors; sympathomimetic agents; lithium; alcohol; sympatholytics including B-blockers; others. See full PI. Side effects: Hypoglycaemia; injection site reactions; visual disturbances; others. See full PI. Dosage and Administration: 26 years. Subcutaneous, once daily. Lantus is equivalent to human insulin. Initial dose determined depending on desired blood glucose levels and doses and timing of any antidiabetic medication. For changeover from once-daily NPH or ultralente, initial dose usually not changed; for changeover from twice-daily NPH to once-daily Lantus, initial dose usually reduced by approximately 20% compared to total daily NPH dose; for initiation of type 2 patients, initial dose usually approximately 10U. Date reviewed: 28 September 2014, References Document: P1, 26 March 2014.


© Toujeo and Lantus are registered trademarks of sanofi-aventis australian Pty Ltd. sanofi-aventis australian Pty Ltd trading as Sanof, ABN 31 008 588 807, Tailors Corporate Centre, Building D, 12–24 Tailors Road, Macquarie Park, NSW 2113 SAVT036 Date of preparation: July 2015 SAAANZ.TJ0.15.07.0191
The HbA1c reduction you can expect from insulin glargine (Lantus® 100 units/mL) is lower risk of hypoglycaemia compared with Lantus in people with type 2 diabetes.
Novo Nordisk Changing Diabetes® Fun Run/Walk
7:00am - 8:00am

This conference acknowledges the sponsorship of Novo Nordisk

The start & finish will be outside the Adelaide Convention Centre in Elder Park.

**Breakfast Sessions - Concurrent**

**Medtronic Trade Breakfast Symposium**
7:30am - 8:45am  Room L1
MiniMed 640G System: the next step in the journey towards the closed loop, providing advanced protection from hypoglycaemia

**Concurrent Sessions**

**ADS & ADEA Joint Symposium: Technology for Motivation, Fitness, Diabetes Management and Beyond**
9:00am - 11:00am  Halls L & M
*Recorded Session*

Chairs: Natalie Wischer & Liz Obersteller

9:00 AM  Adrienne O'Neil
Using ‘smart’ technology to improve the outcomes of people with type 2 diabetes and other chronic conditions.  abs# 177

9:30 AM  Josh Guest
Mobile, Apps and health - 2015/2016  abs# 178

10:00 AM  Stuart Smith
Quantified Health: an overview of digital technologies and gamification to encourage sustained engagement in physical activity  abs# 179

10:30 AM  Panel Discussion

**ADS & ANZOS Joint Symposium: Obesity**
9:00am - 11:00am  Riverbank 6, 7 & 8
*Recorded Session*

Chairs: Jenny Gunton & Brian Oldfield  This conference acknowledges the sponsorship of Novo Nordisk

9:00 AM  Zane Andrews
Carnitine metabolism in hypothalamic neurons is important to maintain energy and glucose homeostasis  abs# 180

9:30 AM  Christine Feinle-Bisset
Nutrient impacts on appetite – insights from human studies  abs# 181

10:00 AM  Joseph Proietto
Weight Loss: Slow and Steady or Fast and Furious  abs# 182

10:30 AM  Cate Lombard
Is preventing weight gain a feasible option to manage obesity?  abs# 183
**ADS Clinical Symposium: Prevention of Type 2 Diabetes**

9:00am - 11:00am  
Riverbank 2, 3 & 4  
*Recorded Session*

**Chairs:** Stephen Stranks & Anthony Russell  
*This conference acknowledges the sponsorship of MSD*

**9:00 AM**  
**Stephen Colagiuri**  
Using old diabetes drugs for prevention of type 2 diabetes.  
abs# 184

**9:30 AM**  
**John Prins**  
Prevention of type 2 diabetes – new agents  
abs# 185

**10:00 AM**  
**Gary Wittert**  
Testosterone and the prevention of type 2 diabetes mellitus (T2DM)  
abs# 186

**10:30 AM**  
**Jacob Chisholm**  
Bariatric surgery for prevention of type 2 diabetes  
abs# 187

**ADS Basic Orals: Lipids, Cytokines and Glucose Tolerance**

9:00am - 11:00am  
Room L1

**Chairs:** Clinton Bruce & Darren Henstridge

**9:00 AM**  
**Stacey N Keenan**  
Perilipin 5 regulates hepatic lipid metabolism and glucose tolerance in mice.  
abs# 188

**9:15 AM**  
**Ruzaidi A.M. Mokhtar**  
Perilipin 5 deletion alters skeletal muscle lipid and glucose metabolism.  
abs# 189

**9:30 AM**  
**Sarah Turpin**  
Targeting C18:0, but not C16:0, ceramides in skeletal muscle to alleviate glucose intolerance  
abs# 190

**9:45 AM**  
**Jingjing He**  
Identification and characterisation of HHIP: A novel regulator of adipogenesis implicated in the modulation of local and systemic insulin sensitivity  
abs# 191

**10:00 AM**  
**Ruth Meex**  
Identification of secreted factors linking hepatic steatosis to insulin resistance.  
abs# 192

**10:15 AM**  
**Tamara L Allen**  
IC7, a designer cytokine, improves glucose tolerance in an insulin dependent manner in high fat fed mice and non human primates  
abs# 193

**10:30 AM**  
**Maria Findeisen**  
IC7, an innovative designer gp130 cytokine and its acute mode of action  
abs# 194

**10:45 AM**  
**Aascha Brown**  
Obesity, insulin resistance and the role of inflammation in cafeteria diet-fed rats.  
abs# 195

**ADS Clinical Orals: Kidney Function in Diabetes**

9:00am - 11:00am  
City Room 3 & 4

**Chairs:** Alicia Jenkins & Karin Jandeleit-Dahm

**9:00 AM**  
**Nicholas Radcliffe**  
Longitudinal Uric Acid Clearance in Patients with Type 1 Diabetes and Preserved Glomerular Filtration Rate  
abs# 196

**9:15 AM**  
**Elif I. Ekinci**  
Neutrophil-Lymphocyte Ratio and C-Reactive Protein levels are increased in patients with diabetic kidney disease  
abs# 197

**9:30 AM**  
**Richard J MacIsaac**  
Soluble Tissue Necrosis Factor Receptor type 1 (sTNFR1) levels and decline in estimated Glomerular Filtration Rate (eGFR) in patients with diabetes  
abs# 198

**9:45 AM**  
**Nicholas Radcliffe**  
Rates of CKD3 Development in Type 1 and Type 2 Diabetes with and without Glomerular Hyperfiltration  
abs# 199

**10:00 AM**  
**Angela Sheu**  
Impact of Diabetes Mellitus and New Onset Diabetes After Transplant on outcomes after Renal Transplantation  
abs# 200

**10:15 AM**  
**Hang D Nguyen**  
Highly-sensitive Troponin T in a cohort of Indigenous Australian adults with and without Diabetes and Chronic Kidney Disease  
abs# 201
### Concurrent Sessions

#### ADS Clinical Trials Update
**11:30am - 1:00pm**  
Chair: Peter Colman  

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
<th>Abs#</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 AM</td>
<td>Jenny E Gunton</td>
<td>Type 1 diabetes and oral agents</td>
<td>204</td>
</tr>
<tr>
<td>11:50 AM</td>
<td>Julio Rosenstock</td>
<td>ELIXA trial results</td>
<td>205</td>
</tr>
<tr>
<td>12:10 PM</td>
<td>Sophia Zoungas</td>
<td>ADVANCE-ON</td>
<td>206</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>John Prins</td>
<td>TECOS – what are the lessons now that the dust has settled?</td>
<td>370</td>
</tr>
</tbody>
</table>

#### Jan Baldwin Oration
**11:30am - 12:15pm**  
Chair: Tracy Aylen  

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
<th>Abs#</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 AM</td>
<td>Deb Foskett</td>
<td>Put Yourself in Their Shoes?</td>
<td>207</td>
</tr>
</tbody>
</table>

#### ADEA Annual General Meeting, CDE of the Year and Award Ceremony
**12:15am - 1:30pm**  
Chair: Tracy Aylen  

#### ADS & ADEA Joint Symposium: Indigenous Health
**11:30am - 1:30pm**  
Chair: Louise Maple-Brown & Liz Obersteller  

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
<th>Abs#</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 AM</td>
<td>Alex Brown</td>
<td>The Burden and Determinants of Diabetes in Indigenous Australians</td>
<td>208</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Mark Shah &amp; Joanna Giles</td>
<td>The Metabolic Symphony Program- the background story of this novel education program</td>
<td>209</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Elizabeth Barr</td>
<td>The Darwin Region Urban Indigenous Diabetes (DRUID) follow-up study: methods, response rates and preliminary findings</td>
<td>210</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Cherie Whitbread</td>
<td>The Northern Territory Diabetes in Pregnancy Partnership – an opportunity of a lifetime.</td>
<td>211</td>
</tr>
</tbody>
</table>
The conference acknowledges the sponsorship of

---

**ADS Clinical Orals: Cardiac and Exercise**
11:30am - 1:30pm
Room L2

Chairs: Stephen Twigg & Sue Lynn Lau

11:30 AM  **Sheila K Patel**
The Kruppel like factor 15 rs9838915 single nucleotide polymorphism is associated with left ventricular hypertrophy and heart failure in patients with type 2 diabetes  abs# 212

11:45 AM  **Richard O'Brien**
Efficacy and Safety of Alirocumab in Individuals with Diabetes: Post-hoc analyses from the ODYSSEY LONG TERM Study  abs# 213

12:00 PM  **Timothy ME Davis**
Heart failure prevalence and incidence in Aboriginals vs Anglo Celts with type 2 diabetes: The Fremantle Diabetes Study Phase II  abs# 214

12:15 PM  **Wendy A Davis**
Generalised anxiety disorder is an independent predictor of cardiovascular mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II  abs# 215

12:30 PM  **Timothy J Roberts**
No evidence of reduced exercise capacity or 'diabetic cardiomyopathy' in type 1 diabetes subjects  abs# 216

12:45 PM  **Agata K Piotrowicz**
An On-line Support Tool Reduces Exercise-Related Hypoglycaemia and Improves Confidence to Exercise in Type 1 Diabetes  abs# 217

1:00 PM  **Joule Li**
Inverse association of grip strength with risk of incident type 2 diabetes mellitus in community-dwelling men  abs# 218

1:15 PM  **S L Williams**
Adults understanding of diabetes and their health information seeking behaviours  abs# 219

---

**ADS Basic Symposium: Cytokines**
11:30am - 1:30pm
City Room 3 & 4

Chairs: Trevor Biden & Helen Thomas

11:30 AM  **Michael McGuckin**
Cytokine regulators of beta-cell stress  abs# 363

12:00 PM  **Helen Thomas**
Dissecting the cytokine responses required for pathogenesis of autoimmune diabetes  abs# 364

12:15 PM  **Leonie Heilbronn**
Cytokines, macrophages and tissue remodelling following nutritional modulation in humans  abs# 365

12:45 PM  **Seth Masters**
IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome  abs# 366

---

**Plenary**

---

**ADS & ADIPS Skip Martin Conjoint Plenary Lectures**
11:30am - 1:30pm
City Room 1 & 2

Chair: Glynis Ross & William Jeffries

This conference acknowledges the sponsorship of Novo Nordisk

11:30 AM  **Linda Barbour**
Maternal Obesity - Optimizing Weight Gain for Maternal and Infant Health — Less is More? abs# 367

12:15 PM  **Leonie Callaway**
Maternal Obesity: new insights  abs# 368

---

**Lunch**
1:30pm - 2:00pm
Foyer L

Lunch Boxes will be provided
ADEA POC Meeting
1:30pm - 2:30pm
Halls L & M

John R Turtle Diabetes Clinical Skills Training Course for Advanced Trainees in Endocrinology
1:30pm - 5:30pm
Room L1 & L2
Lunch will be provided.

ADEA Subcutaneous Injection Technique Guidelines Workshop
1:30pm - 2:30pm
Riverbank 2, 3 & 4
*Recorded Session*
*Pre registration is essential
Chair: Rachel McKeown
1:30 PM  Peta Tauchmann
Subcutaneous Injection Technique Guidelines  abs# 369

This conference acknowledges the sponsorship of Eli Lilly & Servier

Erectile Dysfunction affects
35% to 90% of men with diabetes*

“I was 32, and the doctors told me all the things I could
look forward to... problems with my eyes, heart, kidney,
liver, circulation and eventually ED. Within the first year
I started having problems with ED.”
— Tom Waters

We can help with the conversation
Come and visit us at Stand 8

* Malaviya LS, Levy JC. Erectile dysfunction in diabetes mellitus
™ The denoted marks are trademarks or registered trademarks of
American Medical Systems, LLC. © 2015 American Medical Systems, LLC.
All Rights Reserved, Minnetonka, MN 55343
1800 642 639 Australian and New Zealand Use Only